Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
HUMA · NASDAQ · Biological Products, (No Diagnostic Substances)
Humacyte (HUMA) · oqro.io/stocks/HUMA · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$0.5584−0.037 (−6.21%)
Close of Nov 13, 2026, vs Nov 12 · end-of-day, not a live quote
Yes. Insiders of Humacyte (HUMA) filed 3 open-market purchases in the last 90 days; the latest was filed on Sep 15, 2026.
Since 2021, Humacyte insiders reported 44 open-market purchases and 90 sales on Forms 4 and 5, with purchases in 6 different years, most recently 2026.
No open-market sale by an insider of Humacyte (HUMA) was filed with the SEC in the last 90 days.
No trade in Humacyte (HUMA) was disclosed by a member of Congress in the last 12 months.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
−53.1% (−$0.6316) from Nov 13, 2025 to Nov 13, 2026 · adjusted daily closes
Adjusted close went from $1.19 on Nov 13, 2025 to $0.5584 on Nov 13, 2026 (−53.1%). Disclosed in this range: 5 insider trades, 2 pre-arranged insider sales, 0 Congress trades.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Biological Products, (No Diagnostic Substances) company based in Durham, Nc.
Last 12 months
−53.1%
Market value
$155M
S&P 500 +12.3% over the same dates. Prices adjusted for splits and dividends.
Short interest: 28.1M shares sold short (10.1% of shares outstanding), −7.2% vs the previous count, 7.2 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Revenue
$406K
+34.9% vs the same quarter a year earlier
Free cash flow, last 12 months
−$97.6M
This quarter −$22.2M, a year earlier −$27M
Net cash
$43.6M
Debt $36.3M, cash $79.9M, at Jun 30, 2026
Net income, last 12 months
−$96.7M
Operating profit covers interest -10.8x
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 10, 2026.
Revenue, fiscal 2025
$2.04M
Year ended Dec 31, 2025
Net income, fiscal 2025
−$40.8M
A loss for the year
Shares outstanding
278M
As of Aug 10, 2026
Insider buying
8 days before an 8-KTraded Sep 14 · filed 1 day later
Since the trade −0.5% · S&P 500 −0.9% · to Nov 13
On the public record for Humacyte over the 12 months to Nov 15, 2026: 3 clinical trials.
Notice of delisting or failure to meet listing rules
8-K on sec.govNotice of delisting or failure to meet listing rules
8-K on sec.govFrom the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.
Last results
Nov 10, 2026
Within the 30 days after it, until Dec 10, 2026
Next results, expected
Not announced
Purchases after results
78%
32 of 41 insider purchases since 2021 came within 30 days after a results announcement
From Humacyte's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Humacyte's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
Traded Aug 17 – Aug 20, 2026 · largest single transaction ~$18K
Aug 20, 2026~$6.9K · 10K sh @ $0.693
DetailsOfficial recordAug 17, 2026~$18K · 30K sh @ $0.594
DetailsOfficial recordInsider buying
Bought outside the usual windowTraded May 19 · filed 1 day later
Since the trade −32.3% · S&P 500 +2.8% · to Nov 13
A Humacyte director paid $50K out of pocket for Humacyte shares. 1 other person at Humacyte bought some too, in the same month. Shares held went up 62% with this purchase.
Insider buying
Bought outside the usual windowTraded May 18 · filed 2 days later
Since the trade −37.9% · S&P 500 +2.1% · to Nov 13
A Humacyte director paid $9.8K out of pocket for Humacyte shares. 1 other person at Humacyte bought some too, in the same month. Shares held went up 33% with this purchase.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Insiders of Humacyte reported 44 open-market purchases and 90 sales since 2021; purchases in 6 different years, most recently 2026.
| Year | Bought | Sold |
|---|---|---|
| 2026 | $90K5×5 trades | $82K2×2 trades |
| 2025 | $146K6×6 trades | $7.47M6×6 trades |
| 2024 | $849K |
$55.9M37×37 trades |
| 2023 | $20K1×1 trade | $94.7M22×22 trades |
| 2022 | $765K13×13 trades | $25.9M15×15 trades |
| 2021 | $45.7M5×5 trades | $5.46M8×8 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
2 active phase 3 trials and 1 active phase 2 trial led by this company, mostly in end stage renal disease (esrd), vascular trauma, coronary artery disease. The ones with the nearest registered primary completion date still ahead:
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.
Against the S&P 500 over the year
Since Nov 12, 2025, HUMA is down 55.3% and the index fund is up 10.4%: 66 points behind the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much HUMA moves
End-of-day prices. These figures describe the past year and say nothing about what comes next.